Futuras estrategias terapéuticas en el tratamiento del cáncer de mama metastásico RE+/HER2-negativo: inhibidores CDK4/6 - page 13

Sensitivity to Palbociclib in different human
breast cancer cell lines
Finn RS, et al. Breast Cancer Res 2009
Luminal ER-positive and HER2-amplified breast cancer cell lines and
HER2-amplified breast cancer cell lines are most sensitive to CDK4/6
inhibition of proliferation
0
100
200
300
400
500
600
700
800
900
1000 Luminal
Her2 Amplified
Immortalized
Non-luminal/post EMT
Non-luminal